Bicotin Tablets 1 mg (Varenicline Salicylate)

Adult dose

Patients should set a quit date and start taking this medicine 1 week before that date. Alternatively, they may start quitting between day 8 and day 35 after starting this medicine. This medicine should be taken after meals with plenty of water. The recommended dose of this medicine is as follows: after dose titration over 1 week, take 1 mg twice daily. Days 1 – 3: 0.5 mg once daily Days 4 – 7: 0.5 mg twice daily Day 8 – end of treatment: 1 mg twice daily For patients who cannot tolerate the adverse reactions of this medicine, the dose may be reduced temporarily or permanently. The treatment period is 12 weeks. For patients who successfully quit smoking with the initial 12 weeks of treatment, an additional 12 weeks of treatment with this medicine is recommended to increase the likelihood of long-term abstinence. For patients who cannot or do not wish to stop smoking abruptly, consider gradually stopping smoking while taking this medicine. Within the first 4 weeks after starting this medicine, patients should reduce their smoking by 50% compared with before starting treatment, and reduce it by an additional 50% over the next 4 weeks. Continue to reduce smoking so that complete abstinence is achieved by 12 weeks. Continue treatment with this medicine for an additional 12 weeks, for a total treatment period of 24 weeks. No dose adjustment is necessary in patients with mild (estimated creatinine clearance > 50 ml/min and ≤ 80 ml/min) to moderate (estimated creatinine clearance ≥ 30 ml/min and ≤ 50 ml/min) renal impairment. In patients with severe renal impairment (estimated creatinine clearance < 30 ml/min), the recommended starting dose of varenicline is 0.5 mg once daily. If needed, the maximum dose is 0.5 mg twice daily. In patients with end-stage renal disease undergoing hemodialysis, if well tolerated, a maximum dose of 0.5 mg once daily may be administered. No dose adjustment is necessary in patients with hepatic impairment. In elderly patients, renal function may be more likely to be reduced, so use caution when selecting the dose; monitoring renal function may be useful.

Child dose

Administration is not recommended in patients under 18 years of age.

This medication is used to assist in smoking cessation. During treatment with this medication, special attention should be given to mental health. Serious psychiatric symptoms such as depression, anxiety, agitation, aggression, hallucinations, and suicidal thoughts may occur in some patients. If such symptoms occur, the medication should be discontinued immediately and a physician should be consulted. This medication should not be given to patients with hypersensitivity, and women who are pregnant or breastfeeding should use it cautiously. The most common side effect during the initial dose is nausea, which usually improves from mild to moderate over time. However, some patients may experience prolonged nausea. Symptoms of discomfort, insomnia, anxiety, and concentration difficulties may also be experienced while quitting smoking, and this medication and the quitting process may both affect mental health, so caution is needed. Caution is required when performing hazardous activities such as driving or operating machinery due to the risk of accidents caused by drowsiness or dizziness. This medication has been associated with some cardiovascular abnormalities in patients with cardiovascular diseases; therefore, those with heart conditions or new symptoms should inform their physician immediately. There is little potential for interaction with other medications, but alcohol consumption may enhance effects or result in unusual behavior; thus, alcohol should be avoided or minimized. The risks to the fetus during pregnancy have not been fully established; hence, it should only be used when absolutely necessary and with physician consultation. While breastfeeding, this medication could be passed into breast milk; thus, a discussion with a physician should determine whether to continue breastfeeding or discontinue the medication. Use in patients under 18 is not recommended. Elderly patients may have decreased kidney function, requiring dosage adjustments and regular monitoring of kidney function. In the case of overdose, no specific antidote is available, and appropriate treatment should be conducted based on symptoms; dialysis may be helpful in severe kidney disease. This medication should be stored out of reach of children and kept in its original container to prevent deterioration or misuse.

• Suicidal ideation
• suicidal behavior
• suicide
• changes in behavior or thoughts
• depression
• mania
• mood changes
• psychosis
• aggressive behavior
• hallucinations

This medication should be stored in a tightly sealed container to protect it from air or moisture. Additionally, it should be stored at room temperature between 1 degrees Celsius and 30 degrees Celsius, away from extremes of heat or cold, to maintain its efficacy for a long time.

Appearance

Light blue, biconvex, rectangular film-coated tablet

Package unit

28 tablets (14 tablets/Blister X 2)